Since it comes up often enough, we decided to create a guide that answers exactly that. Who should I see? FebruWe receive emails every day from people wondering who they should see for a wide variety of issues that often go hand-in-hand with Parkinson’s.
LARAMIE BOOMERANG OBITUARIES TRIAL
The investigators behind the Phase III clinical trial reported that the experimental treatment being tested had no effect on the progression of Parkinson’s in recently diagnosed individuals. Isradipine: Posthoc analysis Ma# Last year the results of the large STEADY-PD study were published.The list is based on nothing more than the author’s personal opinion – apologies to any researchers who… Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. 2019: Year in review DecemIn this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019.There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing… This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s.
ADepTing to the UCB-Novartis deal Decem# Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community.
0 kommentar(er)
